/BVX.L
BVX.L Stock - BiVictriX Therapeutics Plc
Healthcare|BiotechnologyLSE
$10.00+17.65%
+$1.50 (+17.65%) • Sep 10
61
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.27
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $11.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BVX.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.90 – $10.10
TARGET (TP)$11.50
STOP LOSS$9.20
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.73
52W High$14.00
52W Low$10.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-165,000 | $-151,000 | $-46,000 | $-1,000 | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,025,000 | $-2,975,000 | $-1,891,000 | $-490,000 | $-526,000 |
| Net Income | $-2,545,000 | $-2,497,000 | $-2,339,000 | $-425,000 | $-409,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.04 | $-0.04 | $-0.04 | $-0.02 | $-0.01 |
Company Overview
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia. The company was formerly known as BiVictriX Plc and changed its name to BiVictriX Therapeutics Plc in August 2021. BiVictriX Therapeutics Plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
BVX.LBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.02
Q3 2024
EPS Surprise History
Q4 21
No data
Q2 22
No data
Q3 22
No data
Q4 22
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2024 | Aug 1, 2024 | — | $-0.02 | — | — |
Q2 2024 | May 3, 2024 | — | — | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.02 | — | — |
Q3 2023 | Sep 19, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.02 | — | — |
Q1 2023 | Mar 30, 2023 | — | — | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.02 | — | — |
Q3 2022 | Sep 12, 2022 | — | $-0.02 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.02 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.03 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.02 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 29, 2020 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BVX.L
What is BVX.L's current stock price?
BiVictriX Therapeutics Plc (BVX.L) is currently trading at $10.00 per share. The stock has moved +17.65% today.
What is the analyst price target for BVX.L?
No analyst price targets are currently available for this stock.
What sector is BiVictriX Therapeutics Plc in?
BiVictriX Therapeutics Plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the LSE exchange.
What is BVX.L's market cap?
BiVictriX Therapeutics Plc has a market capitalization of $0.01 billion, making it a small-cap company.
Does BVX.L pay dividends?
No, BiVictriX Therapeutics Plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVO.L
Advanced Oncotherapy plc
$1.75
Mkt Cap: $0.9B
CEL.L
Celadon Pharmaceuticals Plc
$13.40
Mkt Cap: $0.9B
CNSL.L
Cambridge Nutritional Sciences plc
$1.95
Mkt Cap: $0.5B
DEST.L
Destiny Pharma plc
$3.00
Mkt Cap: $0.3B
INHC.L
Induction Healthcare Group PLC
$9.75
Mkt Cap: $0.9B
MXC.L
MGC Pharmaceuticals Limited
$21.20
Mkt Cap: $0.9B
NSCI.L
NetScientific plc
$53.12
Mkt Cap: $1.3B
RENE.L
ReNeuron Group plc
$3.38
Mkt Cap: $0.2B
SNG.L
Synairgen plc
$0.95
Mkt Cap: $1.2B
TCF.L
Theracryf Plc
$0.20
Mkt Cap: $0.4B
Explore stocks similar to BVX.L for comparison